IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Haematologica

• Publication date

  2010-10-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3324/haematol.2010.025494PMID 20494930PMCID PMC2948091
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms.

  2010cited by this paper
• Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia.

  2010cited by this paper
• Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation.

  2010cited by this paper
• Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia.

  2010influential reference
• Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor.

  2010cited by this paper
• The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.

  2010cited by this paper
• Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations

  2010cited by this paper
• IDH1 Mutations Are Detected in 9.3% of All AML and Are Strongly Associated with Intermediate Risk Karyotype and Unfavourable Prognosis: a Study of 999 Patients

  2009cited by this paper
• IDH1 and IDH2 mutations in gliomas.

  2009cited by this paper
• Prognostic factors in adult patients up to 60 years old with acute myeloid leukemia and translocations of chromosome band 11q23: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup.

  2009influential reference
• Acquired mutations in TET2 are common in myelodysplastic syndromes

  2009cited by this paper
• Mutations of polycomb‐associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia

  2009cited by this paper
• Defining prior therapy in myelodysplastic syndromes and criteria for relapsed and refractory disease: implications for clinical trial design and enrollment.

  2009cited by this paper
• Myelodysplastic syndromes.

  2009cited by this paper
• Mutation in TET2 in myeloid cancers.

  2009cited by this paper
• Recurring mutations found by sequencing an acute myeloid leukemia genome.

  2009cited by this paper
• IDH1 and IDH2 mutations in gliomas.

  2009influential reference
• Mutations of ASXL1 gene in myeloproliferative neoplasms

  2009cited by this paper
• Mutation in TET2 in myeloid cancers.

  2009influential reference
• An Integrated Genomic Analysis of Human Glioblastoma Multiforme

  2008cited by this paper
• Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.

  2008cited by this paper
• A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia.

  2007cited by this paper
• RUNX1 gene mutation in primary myelodysplastic syndrome – the mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome

  2007cited by this paper
• High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics.

  2006cited by this paper
• Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations.

  2005cited by this paper
• Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS)

  2005cited by this paper
• Risk-adapted induction and consolidation therapy in adults with de novo AML aged ≤ 60 years: results of a prospective multicenter trial

  2004cited by this paper
• A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes

  2004cited by this paper
• High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia.

  2004cited by this paper
• A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy.

  2004cited by this paper
• Treatment of patients with low-risk myelodysplastic syndromes using a combination of all-trans retinoic acid, interferon alpha, and granulocyte colony-stimulating factor

  1999influential reference
• International scoring system for evaluating prognosis in myelodysplastic syndromes.

  1997influential reference
• Mutations in the ras proto-oncogenes in patients with myelodysplastic syndromes.

  1994cited by this paper
• FMS mutations in myelodysplastic, leukemic, and normal subjects.

  1990cited by this paper
• Oral iron chelators: prospects for future development.

  1989cited by this paper
• Oral iron chelators: Prospects for future development

  1989cited by this paper
• Censoring distributions as a measure of follow-up in survival analysis.

  1986cited by this paper
• Regression Models and Life-Tables

  year unknowncited by this paper
• Myelodysplastic Syndromes

  year unknowncited by this paper

• Olutasidenib alone or combined with azacitidine in patients with mutant IDH1 myelodysplastic syndrome

  2025cites this paper
• Outcomes of Patients With IDH1-Mutated Myeloid Neoplasms Treated With Olutasidenib.

  2025cites this paper
• NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 2.2025.

  2025cites this paper
• Molecular insights and treatment innovations: Advancing outcomes in acute myeloid leukemia with myelodysplasia‑related changes (Review).

  2025cites this paper
• Contemporary management paradigms and emerging therapeutics for myelodysplastic syndromes/neoplasms

  2025cites this paper
• Therapeutic targeting of chromatin alterations in leukemia and solid tumors

  2025cites this paper
• FDA Approval Summary: Ivosidenib for Treatment of Adult Patients with Relapsed/Refractory Myelodysplastic Syndrome with an IDH1 Mutation.

  2025cites this paper
• This differentiation block will not stand, man: ivosidenib for MDS

  2024cites this paper
• Implications for metabolic disturbances in myelodysplastic syndromes.

  2024cites this paper
• Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome

  2024cites this paper
• The immunobiology of myelodysplastic neoplasms: a mini-review

  2024cites this paper
• Olutasidenib for Adults with Relapsed or Refractory Acute Myeloid Leukaemia with Isocitrate Dehydrogenase 1 Mutation

  2024cites this paper
• The Leukemic Isocitrate Dehydrogenase (IDH) 1/2 Mutations Impair Myeloid and Erythroid Cell Differentiation of Primary Human Hematopoietic Stem and Progenitor Cells (HSPCs)

  2024cites this paper
• Deciphering the Multifaceted Roles and Clinical Implications of 2-Hydroxyglutarate in Cancer.

  2024cites this paper
• SOHO State of the Art Updates and Next Questions: An Update on Higher Risk Myelodysplastic Syndromes.

  2024cites this paper
• Epigenetic dysregulation in cancers by isocitrate dehydrogenase 2 (IDH2).

  2024cites this paper
• Molecular Drivers of Myelodysplastic Neoplasms (MDS)—Classification and Prognostic Relevance

  2023cites this paper
• HDAC6 deacetylates IDH1 to promote the homeostasis of hematopoietic stem and progenitor cells

  2023cites this paper
• Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS).

  2023cites this paper
• The curious case of IDH mutant acute myeloid leukaemia: biochemistry and therapeutic approaches

  2023cites this paper
• Myelodysplastic syndromes

  2022cites this paper
• In Pursuit of Genetic Prognostic Factors and Treatment Approaches in Secondary Acute Myeloid Leukemia—A Narrative Review of Current Knowledge

  2022cites this paper
• Myelodysplastic Syndrome: Diagnosis and Screening

  2022cites this paper
• NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022.

  2022cites this paper
• A predictive model for bone marrow disease in cytopenia based on noninvasive procedures

  2022cites this paper
• Therapeutic approaches for the management of higher risk myelodysplastic syndromes

  2022cites this paper
• The spectrum of genetic mutations in myelodysplastic syndrome: Should we update prognostication?

  2021cites this paper
• Isocitrate dehydrogenase gene variants in cancer and their clinical significance

  2021cites this paper
• Advances in Diagnosis and Risk Stratification of Acute Myeloid Leukemia and Myelodysplastic Syndromes.

  2021cites this paper
• Metabolic adaptations in cancers expressing isocitrate dehydrogenase mutations

  2021cites this paper
• Clinical utility and real-world application of molecular genetic sequencing in the management of patients with acute myeloid leukemia and myelodysplastic syndromes

  2021cites this paper
• Prognosis in Myelodysplastic Syndromes: The Clinical Challenge of Genomic Integration

  2021cites this paper
• Molecular and genomic landscapes in secondary & therapy related acute myeloid leukemia.

  2021cites this paper
• Screening for myeloid mutations in patients with myelodysplastic syndromes and AML with myelodysplasia-related changes

  2021cites this paper
• Genetic and Genomic Landscape of Secondary and Therapy-Related Acute Myeloid Leukemia

  2020cites this paper
• A continuous-time Markov model approach for modeling myelodysplastic syndromes progression from cross-sectional data

  2020cites this paper
• Targeting isocitrate dehydrogenase mutations (IDH) in AML: wielding the double-edged sword of differentiation.

  2020cites this paper
• Evolving therapies for lower-risk myelodysplastic syndromes

  2020cites this paper
• Molecular Landscape of MDS

  2020cites this paper
• NPM1-Mutated Myeloid Neoplasms with <20% Blasts: A Really Distinct Clinico-Pathologic Entity?

  2020cites this paper
• Analysis 0f TET-2, ASXL1, IDH1, IDH2 Gene Polymorphisms and The Correlation with Clinical Parameters in Patients With Myelodysplastic Syndrome

  2020influential citation
• Gene of the month: IDH1

  2020cites this paper
• Mutations in myelodysplastic syndromes: Core abnormalities and CHIPping away at the edges

  2020cites this paper
• New Agents in the Treatment of Acute Myeloid Leukemia

  2020cites this paper
• Isocitrate Dehydrogenase 2 Inhibitors for the treatment of Hematologic Malignancies: Advances and Future Opportunities.

  2020cites this paper
• IDH1 mutation contributes to myeloid dysplasia in mice by disturbing heme biosynthesis and erythropoiesis.

  2020cites this paper
• Licochalcone A suppresses the proliferation of sarcoma HT-1080 cells, as a selective R132C mutant IDH1 inhibitor.

  2019cites this paper
• Functional and topographic effects on DNA methylation in IDH1/2 mutant cancers

  2019cites this paper
• Do next-generation sequencing results drive diagnostic and therapeutic decisions in MDS?

  2019cites this paper
• Diagnostik und Management der myelodysplastischen Syndrome*

  2019cites this paper
• Diagnostik und Management des myelodysplastischen Syndroms

  2019cites this paper
• Metabolic Reprogramming in Breast Cancer and Its Therapeutic Implications

  2019cites this paper
• What are the most promising new agents in myelodysplastic syndromes?

  2019cites this paper
• Dysregulation of the TET family of epigenetic regulators in hematopoietic malignancies.

  2019cites this paper
• Emerging drug profile: Krebs cycle and cancer: IDH mutations and therapeutic implications

  2019cites this paper
• Acute myeloid leukemia with isolated del(5q) is associated with IDH1/IDH2 mutations and better prognosis when compared to acute myeloid leukemia with complex karyotype including del(5q)

  2019cites this paper
• An evaluation of enasidenib for the treatment of acute myeloid leukemia

  2019cites this paper
• Functional evaluation of isocitrate dehydrogenase 1 and 2 variants of unclear significance in chronic myeloid neoplasms.

  2019cites this paper
• In vivo efficacy of mutant IDH1 inhibitor HMS-101 and structural resolution of distinct binding site

  2019cites this paper
• High expression of PIM2 induces HSC proliferation in myelodysplastic syndromes via the IDH1/HIF1-α signaling pathway

  2019cites this paper
• The long road: the autophagic network and TP53/ASXL1 aberrations in hematopoietic malignancies

  2018cites this paper
• Diagnosis and Prognosis: Molecular

  2018cites this paper
• The Synonymous Isocitrate Dehydrogenase 1 315C>T SNP Confers an Adverse Prognosis in Egyptian Adult Patients with NPM1-/CEBPA-Negative Acute Myeloid Leukemia

  2018cites this paper
• Enasidenib.

  2018cites this paper
• Genetic alterations crossing the borders of distinct hematopoetic lineages and solid tumors: Diagnostic challenges in the era of high-throughput sequencing in hemato-oncology.

  2018cites this paper
• Clinical Significance of DNA Variants in Chronic Myeloid Neoplasms: A Report of the Association for Molecular Pathology.

  2018cites this paper
• From cellular morphology to molecular and epigenetic anomalies of myelodysplastic syndromes

  2018cites this paper
• Molecular pathophysiology of the myelodysplastic syndromes: insights for targeted therapy.

  2018cites this paper
• Phe354Leu Polymorphism of LKB1 Is a Potential Prognostic Factor for Cytogenetically Normal Acute Myeloid Leukemia.

  2017cites this paper
• Roles of the Immune Cytokine Environment on Clonal Growth of Murine and Human Tet2 Mutant Bone Marrow Progenitors: Implications for Myelodysplastic Syndromes

  2017cites this paper
• Targeted Differentiation Therapy with Mutant IDH Inhibitors: Early Experiences and Parallels with Other Differentiation Agents

  2017cites this paper
• Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.

  2017cites this paper
• Comprehensive genomic profiling of different subtypes of nasopharyngeal carcinoma reveals similarities and differences to guide targeted therapy

  2017cites this paper
• Hydroxymethylcytosine correlates with epigenetic regulatory mutations , but may not have prognostic value in predicting survival in normal karyotype acute myeloid leukemia

  2017cites this paper
• The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia

  2017cites this paper
• Characterization of IDH1 p.R132H Mutant Clones Using Mutation-specific Antibody in Myeloid Neoplasms

  2017cites this paper
• The Myelodysplastic Syndromes and the Myelodysplastic/Myeloproliferative Neoplasms

  2017cites this paper
• Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo

  2017cites this paper
• Individual risk assessment in MDS in the era of genomic medicine.

  2017cites this paper
• IDH1 Mutation Is an Independent Inferior Prognostic Indicator for Patients with Myelodysplastic Syndromes

  2017cites this paper
• TP53 mutations predict decitabine‐induced complete responses in patients with myelodysplastic syndromes

  2017cites this paper
• Altered EZH2 splicing and expression is associated with impaired histone H3 lysine 27 tri-Methylation in myelodysplastic syndrome.

  2017cites this paper
• Imaging and Metabolism

  2017cites this paper
• Epigenetics in myelodysplastic syndromes.

  2017cites this paper
• Somatic Mutations in Myelodysplastic Syndrome Patients in the Context of Allogeneic Stem Cell Transplantation

  2016cites this paper
• IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives

  2016cites this paper
• Isocitrate dehydrogenase mutations in myeloid malignancies

  2016cites this paper
• Estudo do perfil genético de pacientes com Neoplasias Mieloproliferativas (NMP) cromossomo Filadélfia negativo

  2016cites this paper
• IDH mutations in cancer and progress toward development of targeted therapeutics.

  2016cites this paper
• Sensitivity of hematopoietic stem cells to mitochondrial dysfunction by SdhD gene deletion

  2016cites this paper
• Emerging biological therapies for the treatment of myelodysplastic syndromes

  2016cites this paper
• The myelodysplastic syndromes

  2016cites this paper
• Roles of IDH1/2 and TET2 mutations in myeloid disorders

  2016cites this paper
• Construction of polycythemia vera protein interaction network and prediction of related biological functions.

  2016cites this paper
• DNMT3A R882 Mutation with FLT3-ITD Positivity Is an Extremely Poor Prognostic Factor in Patients with Normal-Karyotype Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation.

  2016cites this paper
• Pretreatment d-2-hydroxyglutarate serum levels negatively impact on outcome in IDH1-mutated acute myeloid leukemia

  2016cites this paper
• Genetic and Epigenetic Drug Targets in Myelodysplastic Syndromes.

  2016cites this paper
• Association between Transfusion Status and Overall Survival in Patients with Myelodysplastic Syndromes: A Systematic Literature Review and Meta-Analysis

  2016cites this paper
• 5-Hydroxymethylcytosine correlates with epigenetic regulatory mutations, but may not have prognostic value in predicting survival in normal karyotype acute myeloid leukemia

  2016cites this paper
• Insight into the molecular pathophysiology of myelodysplastic syndromes: targets for novel therapy

  2016influential citation